

KERYX BIOPHARMACEUTICALS INC
 Form 4
 December 31, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Oliviero James F III

(Last) (First) (Middle)

C/O KERYX
 BIOPHARMACEUTICALS,
 INC., 750 LEXINGTON AVENUE

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 KERYX
 BIOPHARMACEUTICALS INC
 [KERX]

3. Date of Earliest Transaction
 (Month/Day/Year)
 12/27/2013

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
 Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount		
					(A) or (D)		
					Price		
Common Stock	12/27/2013		S		30,000 (1)	D	Indirect Beneficial Ownership
					\$ 12.68 (2)		
Common Stock	12/30/2013		S		49,500 (1)	D	Indirect Beneficial Ownership
					\$ 12.62 (4)		
Common Stock (Exercise)	12/30/2013		M		30,000 (5)	A	Indirect Beneficial Ownership
					\$ 4.59		

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Sale of a total of 79,500 shares of common stock was made in order to satisfy Mr. Oliviero's income tax withholding obligation upon the vesting of 150,000 shares of restricted stock on a corporate milestone. Such sale was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.

- (1) Reflects the weighted average sale price. The range of prices for such transaction is \$12.65 to \$12.82.
- (2) Includes 296,537 shares of restricted stock.
- (3) Reflects the weighted average sale price. The range of prices for such transaction is \$12.60 to \$12.72.
- (5) Reflects the exercise and sale of 30,000 stock options which were due to expire on January 2, 2014 (10 years following their grant date).
- (6) Reflects the weighted average sale price. The range of prices for such transaction is \$12.60 to \$12.74.
- (7) Following the transactions reported on this Form 4, Mr. Oliviero holds 476,429 shares of Keryx common stock (of which 296,537 are restricted shares) and 327,616 stock options.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.